Methods for screening solid tumors for mutations

Patent metadata

Field	Value
Publication number	US-10689710-B2
Application number	US-201515576219-A
Country	US
Kind code	B2
Filing date	Oct 28, 2015
Priority date	May 27, 2015
Publication date	Jun 23, 2020
Grant date	Jun 23, 2020

Abstract

The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.

First claim

The invention claimed is:

1. A method for detecting at least one mutation in a plurality of cancer-related genes in a subject comprising
(a) extracting genomic DNA from a formalin fixed paraffin-embedded tumor sample obtained from the subject;
(b) generating a library comprising amplicons corresponding to each of the plurality of cancer-related genes, said plurality of cancer-related genes comprising AKT1, ERBB2, FOXL2, IDH2, NRAS, RET, ALK, ERBB4, GNA11, KIT, PDGFRA, SMO, BRAF, FBXW7, GNAQ, KRAS, PIK3CA, STKl1, CTNNB1, FGFR2, GNAS, MAP2K1, PIK3R1, TP53, DDR2, FGFR3, HRAS, MET, PTCH1, EGFR, FGFR4, IDH1, NOTCH1, and PTEN, wherein the amplicons are generated in a multiplex amplification reaction using primer pairs specific for each of the cancer-related genes and wherein at least two of the primer pairs are selected from the group consisting of the primers of SEQ ID NOS: 1-18, 45-54, and 71-274 or the group consisting of the primers of SEQ ID NOS: 19-44, 55-70, and 275-464, wherein:
(i) generating said library proceeds independently of using a bait set comprising nucleic acid sequences that are complementary to at least one of the plurality of amplicons; and
(ii) the quality of the genomic DNA extracted from the formalin fixed paraffin-embedded tumor sample is not assessed using quantitative PCR prior to generating the library;

(c) ligating an adapter sequence to the ends of the plurality of amplicons; and
(d) detecting at least one mutation in at least one of the plurality of amplicons using high throughput massive parallel sequencing.

2. The method of claim 1 , wherein the library comprising amplicons corresponding to each of the plurality of cancer-related genes is generated using no more than 10 ng of extracted genomic DNA from the formalin fixed paraffin-embedded tumor sample.

3. The method of claim 1 , wherein the library comprising amplicons corresponding to each of the plurality of cancer-related genes is generated using 11-25 ng of extracted genomic DNA from the formalin fixed paraffin-embedded tumor sample.

4. The method of claim 1 , wherein the high throughput massive parallel sequencing is performed using pyrosequencing, reversible dye-terminator sequencing, SOLiD sequencing, Ion semiconductor sequencing, Helioscope single molecule sequencing, sequencing by synthesis, or sequencing by ligation.

5. The method of claim 1 , wherein the adapter sequence is a P5 adapter, P7 adapter, P1 adapter, A adapter, or barcode adapter.

6. The method of claim 1 , wherein the plurality of amplicons further comprise a unique index sequence.

7. The method of claim 1 , wherein the formalin fixed paraffin-embedded tumor sample is a heterogeneous tumor.

8. The method of claim 7 , wherein 5% of the cells of the heterogeneous tumor harbor at least one mutation in at least one of the plurality of amplicons.

9. The method of claim 1 , wherein the subject is diagnosed with breast cancer, melanoma, colorectal cancer or lung cancer.

10. The method of claim 1 , wherein the formalin fixed paraffin-embedded specimen is a heterogeneous tumor.

11. The method of claim 10 , wherein 5%-10% of the cells of the heterogeneous tumor harbor at least one mutation in at least one of the plurality of amplicons.

12. The method of claim 1 , wherein the subject is diagnosed as having HER-2 negative breast cancer.

13. The method of claim 1 , wherein the subject is diagnosed as having colorectal cancer.

14. The method of claim 1 , wherein subject is diagnosed as having melanoma.

Assignees

• Quest Diagnostics Invest Inc

Inventors

• Sanders Heather
• Qu Kevin
• Prentice James
• Waldman Frederic

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title